Khati I, Jacquier A, Cadour F, Bartoli A, Graber M, Hardwigsen J, Tradi F, Barral P-A
Department of Radiology, CHU Timone 2, Marseille APHM, Marseille, France.
Department of Surgery, CHU Timone 2, Marseille APHM, Marseille, France.
CVIR Endovasc. 2022 Dec 8;5(1):63. doi: 10.1186/s42155-022-00338-7.
To evaluate primary patency at 12 months after endovascular therapies in hepatic artery stenosis.
A retrospective review of all endovascular interventions for hepatic artery stenosis (HAS) after liver transplantation that occurred between June 2013 and November 2020 was performed at a single institution in France. Follow up occurred from 1 month to 4 years (median 15 months). The treatment consisted of dilation with a balloon or stent. We analyzed short-term (technical success and complications) and long-term outcomes (liver function, arterial patency, graft survival at 12 months (GS), and reintervention). We also compared percutaneous balloon angioplasty (PBA) with stent placement. PBA alone was used if < 30% residual stenosis of the hepatic artery was achieved. Stenting was performed if there was greater than 30% residual stenosis and in the case of complications (dissection or rupture).
A total of 18 stenoses were suspected on the basis of routine surveillance duplex ultrasound imaging (peak systolic velocity > 200 cm/s, systolic accelerating time > 10 ms and resistive index < 0.5), all of which were confirmed by angio CT, but only 17 were confirmed by angiography. Seventeen patients were included (14 males, mean age 57 years; and three females, mean age 58 years). Interventions were performed in 17 cases (95%) with PBA only (5/17), stent only (5/17) or both (4/17). Immediate technical success was 100%. Major complications occurred in 1 of 17 cases (5.8%), consisting of target vessel dissection. The analysis of the three (groups PBA only, stent only or both) showed the same procedural success (100%), GS (100%) and normal liver function after the procedures but different rates of complications (20% vs. 0% vs. 0%), arterial patency at 12 months (60% vs. 80% vs. 85%) (p = 0.4), early stenosis (40% vs. 80% vs. 0%) or late stenosis (60% vs. 20% vs. 100%) and requirement for reintervention (40% vs. 20% vs. 14%) (p = 0.56).
This study suggests that PBA, stent, or both procedures show the same primary patency at 12 months. It is probably not a definitive answer, but these treatments are safe and effective for extending graft survival in the context of graft shortages.
评估肝动脉狭窄血管内治疗后12个月时的初始通畅率。
在法国的一家单一机构对2013年6月至2020年11月期间肝移植后发生的所有肝动脉狭窄(HAS)的血管内介入治疗进行回顾性分析。随访时间为1个月至4年(中位时间15个月)。治疗方法包括球囊扩张或支架置入。我们分析了短期(技术成功率和并发症)和长期结果(肝功能、动脉通畅率、12个月时的移植物存活率(GS)和再次干预情况)。我们还比较了经皮球囊血管成形术(PBA)和支架置入术。如果肝动脉残余狭窄<30%,则单独使用PBA。如果残余狭窄大于30%或出现并发症(夹层或破裂),则进行支架置入。
基于常规监测的双功超声成像(收缩期峰值流速>200 cm/s、收缩期加速时间>10 ms和阻力指数<0.5)共怀疑有18处狭窄,所有这些狭窄均经血管CT证实,但只有17处经血管造影证实。纳入17例患者(14例男性,平均年龄57岁;3例女性,平均年龄58岁)。17例患者进行了干预(95%),仅行PBA(5/17)、仅行支架置入(5/17)或两者都进行(4/17)。即刻技术成功率为100%。17例中有1例(5.8%)发生了主要并发症,为靶血管夹层。对三组(仅PBA组、仅支架置入组或两者都进行组)的分析显示,手术成功率(100%)、GS(100%)和术后肝功能正常情况相同,但并发症发生率不同(20% vs. 0% vs. 0%)、12个月时的动脉通畅率不同(60% vs. 80% vs. 85%)(p = 0.4)、早期狭窄率不同(40% vs. 80% vs. 0%)或晚期狭窄率不同(60% vs. 20% vs. 1OO%)以及再次干预需求不同(40% vs. 20% vs. 14%)(p = 0.56)。
本研究表明,PBA、支架或两种手术方法在12个月时显示出相同的初始通畅率。这可能不是一个确定的答案,但在移植物短缺的情况下,这些治疗方法对于延长移植物存活是安全有效的。